The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
Open accessAbstract
The response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and progesterone receptor (PR) status. ER-positive/PR-negative breast cancers respond less well to selective ER modulator (SERM) therapy than ER-positive/PR-positive tumors. The predictive value of PR has long been attributed to the dependence of PR expression on ER activity, with the absence of PR reflecting a nonfunctional ER and resistance to hormonal therapy. However, recent clinical and laboratory evidence suggests that ER-positive/PR-negative breast cancers may be specifically resistant to SERMs, whereas they may be less resistant to estrogen withdrawal therapy with aromatase inhibitors, which is a result inconsistent with the nonfunctional ER theory. Novel alternative molecular mechanisms potentially explaining SERM resistance in ER-positive/PR-negative tumors have been suggested by recent experimental indications that growth factors may downregulate PR levels. Thus, the absence of PR may not simply indicate a lack of ER activity, but rather may reflect hyperactive cross talk between ER and growth factor signaling pathways that downregulate PR even as they activate other ER functions. Therefore, ER-positive/PR-negative breast tumors might best be treated by completely blocking ER action via estrogen withdrawal with aromatase inhibitors, by targeted ER degradation, or by combined therapy targeting both ER and growth factor signaling pathways. In this review, we will discuss the biology and etiology of ER-positive/PR-negative breast cancer, highlighting recent data on molecular cross talk between ER and growth factor signaling pathways and demonstrating how PR might be a useful marker of these activities. Finally, we will consider the clinical implications of these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wong, C.-W., McNally, C., Nickbarg, E., Komm, B. S., & Cheskis, B. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192569699 · Cited by 324
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Gene regulation by steroid hormones
Beato, M. (1989) · Cell · doi:10.1016/0092-8674(89)90237-7 · Cited by 3,383
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Anderson, R. G. W. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.199 · Cited by 1,942
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Self-citationMolecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Self-citationFGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Progesterone receptor modulates ERα action in breast cancer
Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., Serandour, A. A., Birrell, S. N., Bruna, A., Saadi, A., et al. (2015) · Nature · doi:10.1038/nature14583 · Cited by 659
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Molecular Classification of Breast Cancer
Tsang, J. Y. S., & Tse, G. M. (2020) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000232 · Cited by 556
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Self-citationLim, S., Janzer, A., Becker, A., Zimmer, A., Schüle, R., Buettner, R., & Kirfel, J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp324 · Cited by 470
Sieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D., deFazio, A., Goodman, M. T., Høgdall, E., Deen, S., Wentzensen, N., Moysich, K. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70253-5 · Cited by 433
Filardo, E. J., Graeber, C. T., Quinn, J. A., Resnick, M. B., Giri, D., DeLellis, R. A., Steinhoff, M. M., & Sabo, E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0860 · Cited by 361
Parise, C. A., Bauer, K. R., Brown, M. M., & Caggiano, V. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00822.x · Cited by 331
Molecular and Cellular Heterogeneity in Breast Cancer
Rivenbark, A. G., O’Connor, S. M., & Coleman, W. B. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.002 · Cited by 327
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Schrijver, W. A. M. E., Suijkerbuijk, K. P. M., van Gils, C. H., van der Wall, E., Moelans, C. B., & van Diest, P. J. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx273 · Cited by 306
Yip, C.-H., Smith, R. A., Anderson, B. O., Miller, A. B., Thomas, D. B., Ang, E.-S., Caffarella, R. S., Corbex, M., Kreps, G. L., McTiernan, A., et al. (2008) · Cancer · doi:10.1002/cncr.23842 · Cited by 301
FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival
Badve, S., Turbin, D., Thorat, M. A., Morimiya, A., Nielsen, T. O., Perou, C. M., Dunn, S., Huntsman, D. G., & Nakshatri, H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0122 · Cited by 272
The Role of Progesterone Receptors in Breast Cancer
Li, Z., Wei, H., Li, S., Wu, P., & Mao, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s336643 · Cited by 264
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Self-citation
Metadata
- Authors
- Cui, X., Schiff, R., Arpino, G., Osborne, C. K., & Lee, A. V.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-20
- Volume
- 23
- Issue
- 30
- Pages
- 7721-7735
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2063874882
- Cited by
- 514
- References
- 142
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.